怎么用matrigel 胶做抗新生血管生成。
Abstract.
Efficient
in vitro and in vivo angiogenesis assays,
to assess and compare anti-angiogenic activity are a prerequisite
for the discovery and characterization of anti-angiogenic
targets. Here we describe an optimized Matrigel plug assay
based on subcutaneously implanted chambers and two fast
and reproducible measuring techniques. Plexiglas ring/nylon
net filter-chambers (0.2 ml) containing growth factor-reduced
Matrigel and 300 ng basic fibroblast growth factor (bFGF)
were subcutaneously implanted into the right flank of rats.
Chamber angiogenesis was scored on day 5 and day 10 postimplantation
by computer image analysis of the chamber, and
by optical density reading at 415 nm of a PBS solution of the
chamber content. bFGF significantly induced chamber angiogenesis
and histological examination confirmed that numerous
blood vessels were present in the bFGF-induced chambers.
The anti-angiogenic control compound TNP-470 (10 mg/kg/d
s.c.) completely inhibited the bFGF-induced angiogenesis.
In contrast, the anti-inflammatory or immuno-suppressive
compounds cyclosporin A (15 mg/kg/d p.o.), indomethacin
(1 mg/kg/d p.o.), and prednisolone (5 mg/kg/d p.o.) showed
no anti-angiogenic activity, indicating that the bFGF-induced
angiogenesis was not driven by an inflammatory response
or by a foreign body reaction. Finally, two candidate antiangiogenic
compounds were tested in the assay. Continuous
low-dose therapy with cyclophosphamide (25 mg/kg/d p.o.)
significantly inhibited bFGF-induced angiogenesis, whereas
1
·,25-dihydroxyvitamin D3 (0.5 μg/kg/d p.o.) showed no
significant anti-angiogenic activity. In conclusion, this in vivo
chamber angiogenesis assay is a useful new tool for drug
evaluation as well as research into anti-angiogenesis.
附件: In vivo chamber angiogenesis assay An optimized Matrigel plug ....pdf (2007-1-25 21:28, 158.01 K)
该附件被下载次数 2
